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Abstract
Background: Although propofol is commonly used for general anaesthesia of normothermic
patients in clinical practice, little information is available in the literature regarding the use of
propofol anaesthesia for intracranial decompression using brain hypothermia treatment. A novel
propofol anaesthesia scheme is proposed that should promote such clinical application and improve
understanding of the principles of using propofol anaesthesia for hypothermic intracranial
decompression.
Methods: Theoretical analysis was carried out using a previously-developed integrative model of
the thermoregulatory, hemodynamic and pharmacokinetic subsystems. Propofol kinetics is
described using a framework similar to that of this model and combined with the thermoregulation
subsystem through the pharmacodynamic relationship between the blood propofol concentration
and the thermoregulatory threshold. A propofol anaesthesia scheme for hypothermic intracranial
decompression was simulated using the integrative model.
Results: Compared to the empirical anaesthesia scheme, the proposed anaesthesia scheme can
reduce the required propofol dosage by more than 18%.
Conclusion: The integrative model of the thermoregulatory, hemodynamic and pharmacokinetic
subsystems is effective in analyzing the use of propofol anaesthesia for hypothermic intracranial
decompression. This propofol infusion scheme appears to be more appropriate for clinical
application than the empirical one.
Background
High intracranial pressure (ICP) is still a major cause of
mortality in the intensive care unit [1]. Achieving a sus-
tained reduction in ICP in patients with intracranial
hypertension remains a great challenge in clinical prac-
tice. Brain hypothermia treatment has been demonstrated
to be especially effective for patients with refractory intrac-
ranial hypertension, for whom conventional therapeutic
options for decompression have failed [2]. About half of
hypothermia treatments were introduced for the purpose
of controlling refractory intracranial hypertension [3].
Besides the management of intracranial temperature and
pressure, the administration of anaesthesia is another
important task in therapeutic hypothermia treatment.
Propofol is widely used in clinical practice for brain hypo-
thermia treatment [4]. However, the rates of propofol
administration are based mainly on clinical experience
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and the normothermic dosage guidelines. An empirical
but practical scheme, known as Roberts' step-down infu-
sion, consists of a loading dose of 1 mg kg-1 body weight
followed immediately by an infusion of 10 mg kg-1 h-1 for
10 minutes, 8 mg kg-1 h-1 for the next 10 minutes, and 6
mg kg-1 h-1 thereafter [5].
However, the propofol kinetics of hypothermic patients
differs significantly from that of normothermic patients
because the enzymes that metabolize most drugs are tem-
perature-sensitive [6]. Blood propofol concentrations
averaged 28% more at 34°C than at 37°C in healthy vol-
unteers, partially because of the hypothermia-induced
decrease in propofol clearance [7]. At the same time, pro-
pofol kinetics is clinically affected by hypothermia
because therapeutic cooling causes hemodynamic
changes. Therefore, a propofol administration scheme
used in conjunction with therapeutic cooling should
improve the clinical use of propofol anaesthesia for hypo-
thermic intracranial decompression.
The effects of hypothermia on propofol kinetics have not
been taken into account theoretically, although some
physiologically-based pharmacokinetic (PBPK) models
for propofol have been developed recently [8,9]. To the
best of our knowledge, theoretical analysis of the use of
propofol anaesthesia for hypothermic intracranial decom-
pression is still unavailable in the literature.
On the other hand, an integrative model of the ther-
moregulatory subsystem, the hemodynamic subsystem
and the pharmacokinetic subsystem for a diuretic (manni-
tol) has been developed for patients undergoing brain
hypothermia treatment [10,11]. Hypothermic intracranial
decompression was quantitatively characterized by a
transfer function [10]. A decoupling control of intracra-
nial temperature and pressure was also established to real-
ize systemic management of cooling and diuresis [11].
We have now used this previously-developed integrative
model to analyze the use of propofol anaesthesia for
hypothermic intracranial decompression. The pharmaco-
dynamic relationship between the temperature threshold
of thermoregulatory reaction (the core temperature trig-
gering vasoconstriction or shivering) and the blood pro-
pofol concentration is used to combine the
thermoregulatory subsystems with the propofol kinetics.
Using the integrative model, a new scheme of propofol
anaesthesia for hypothermic intracranial decompression
is proposed. Simulations demonstrate the effectiveness of
this scheme, and the results suggest that it is more appro-
priate for clinical application than the empirical Roberts'
scheme.
Model
Relationship between thermoregulatory threshold and 
blood propofol concentration
In patients without anaesthesia, vasoconstriction and
shivering begin when the core body temperature drops
below the thermoregulatory threshold. In brain hypother-
mia treatment, vasoconstriction is related to high periph-
eral vascular resistance, inadequate peripheral blood
infusion and high mean arterial blood pressure, while
shivering increases metabolism and disturbs cardiopul-
monary function. Shivering may also cause a transient
increase in ICP. Therefore, both vasoconstriction and
shivering should be prevented by using anaesthesia dur-
ing hypothermia treatment.
The duration of action of propofol is short and recovery is
rapid because of its rapid distribution and clearance [12].
Compared to other sedatives, propofol provides effective
sedation with a more rapid and predictable emergence
time for sedation for adults in a variety of clinical settings.
Therefore, propofol is widely used in clinical practice.
Generally, there is a good correlation between blood pro-
pofol concentration and depth of anaesthesia, and contin-
uous infusions of propofol increase the depth in a dose-
dependent manner [12].
Matsukawa and colleagues [13] made a systemic investi-
gation of thermoregulation under propofol anaesthesia
and found that propofol markedly reduced the vasocon-
striction and shivering thresholds. The relationship
between the thermoregulatory threshold and propofol
concentration in blood can be described mathematically:
Tthres = T0thres - σCartery
where Cartery (µg ml-1) denotes the plasma propofol con-
centration, which is assumed hereafter to be equal to the
blood propofol concentration, σ is the slope (σ = 0.6°C
(µg ml-1)-1 for vasoconstriction and 0.7°C (µg ml-1)-1 for
shivering),  Tthres (°C) is the thermoregulatory response
threshold and T0thres is its initial value. It was estimated
that T0thres = 36.5°C for vasoconstriction and 35.6°C for
shivering [13].
Because the direct pharmacodynamic effects of propofol
on neuroprotection are ignored here for simplification,
(1) implies that administration of propofol anaesthesia is
unnecessary unless the cooled core temperature, repre-
sented here by the brain temperature, is below 36.5°C,
the threshold of vasoconstriction. In other words, if the
brain temperature is below the temperature threshold
determined by the blood propofol concentration, addi-
tional propofol should be administered.Theoretical Biology and Medical Modelling 2007, 4:46 http://www.tbiomed.com/content/4/1/46
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The propofol-threshold mechanism represented by (1) com-
bines the thermoregulatory subsystem with propofol
kinetics pharmacodynamically. It hints at how a patient
undergoing hypothermia treatment should be anaesthe-
tized in order to realize stable management of pathophys-
iological function. If we assume that the brain
temperature of a hypothermic patient is slightly (for
example, 0.01°C) higher than the temperature threshold
determined by the blood propofol concentration, the
minimum blood propofol concentration necessary for
hypothermic intracranial decompression can be calcu-
lated directly using (1).
Model description
Structure and assumptions
The dynamics of the thermoregulatory, hemodynamic
and pharmacokinetic subsystems of a patient undergoing
brain hypothermia treatment has been modelled previ-
ously [10,11]. As shown in Fig. 1, the model is composed
of 6 segments or 13 lumped compartments. A cooling
blanket is assumed to be applied to the mass compart-
ment of the muscular segment, while the temperature and
hydrostatic pressure in the cerebrospinal fluid (CSF) com-
partment are considered to represent brain temperature
and ICP.
Previously, hypothermic effects on the hemodynamics
and the pharmacokinetics of diuretic (mannitol) have
been considered in order to realize simultaneous control
of intracranial temperature and pressure [11]. Here, the
thermoregulatory and hemodynamic parts of the integra-
tive model are used without change, while the diuretic
kinetic part is changed to describe the propofol kinetics,
mainly by changing the pharmacokinetic parameters. Sev-
eral assumptions are made in modelling the propofol
kinetics.
Propofol is administered into the venous compartment
and eliminated from the visceral blood compartment. The
permeability coefficient of propofol across the vascular
wall and the total body clearance are temperature-
Structure of integrative model Figure 1
Structure of integrative model. Elevated ICP is reduced by therapeutic cooling [11]. Brain temperature, represented by CSF 
temperature, is reduced owing to therapeutic cooling. Propofol is administered into venous part of cardiocirculatory segment 
to achieve the minimum blood propofol concentration needed to inhibit thermoregulatory responses.
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dependent, as described by the Arrhenius or Van't Hoff
equation, as previously reported [10,11].
The main site of propofol action on the thermoregulatory
response is the central nervous system. However, the level
of anaesthesia has to be estimated from the propofol con-
centration in the blood, not in the brain mass. Firstly and
mainly, this is because the blood propofol concentration
is clinically measurable, while measuring the brain propo-
fol concentration in people entails obvious practical and
ethical problems. Secondly, the propofol concentration in
the CSF can be measured, but it is different in kind from
the concentration in brain mass owing to the high pro-
tein-binding rate of propofol in brain mass. Moreover,
such measurement is still infrequent in clinical practice
because accessibility to CSF is limited [14]. Lastly, the pro-
pofol-threshold mechanism is conveniently based on the
blood propofol concentration.
Generally, propofol is associated with good hemody-
namic stability although it induces a dose-dependent
decrease in systemic vascular resistance, blood pressure
and heart rate, together with total body oxygen consump-
tion [12,15]. Hypothermia also reduces the metabolic
rate. Therefore, hypothermia and propofol used concur-
rently have an additive effect on metabolism [16]. For
simplicity, however, the direct effects of propofol on brain
metabolism and ICP are ignored. Although the hydro-
static pressures of the various compartments vary with
respect to therapeutic cooling, it is assumed that vascular
resistances are constant during anaesthesia and hypother-
mia.
Governing equation
Because the thermoregulatory and hemodynamic parts of
the integrative model are used unchanged, only the pro-
pofol kinetics is described (see Appendix). The propofol
kinetics is represented systemically by
where V ∈ R13x13 is a diagonal matrix corresponding to the
distribution volume of propofol in each of the 13 com-
partments, C(t) ∈ R13x1 is the state variable vector of the
propofol concentration in each compartment, and
A(T,P,t) ∈ R13x13 is a time-varying coefficient matrix deter-
mined by both the pharmacokinetic parameters and the
physiological states of the thermoregulatory and hemody-
namic subsystems. The interactions among the various
subsystems are involved in matrix A through a tempera-
ture-dependent mechanism as well as through blood
flow. The input vector, u(t) ∈ R13x1, represents propofol
infusion into the venous compartment.
Combining equation (2) with mathematical descriptions
of the thermoregulatory and hemodynamic subsystems
produces an integrative model consisting of 39 differen-
tial equations. It was programmed in Visual C++ (Version
6.0). Runge-Kutta integration was used to solve these
equations numerically.
Pharmacokinetic parameters
Data for the integrative model were mainly taken from the
literature. The physical and physiological parameters for
the thermoregulatory and hemodynamic subsystems are
described elsewhere [10,11]. The pharmacokinetic param-
eters of propofol, including the permeability coefficient,
total body clearance, tissue/water partition coefficient,
lung sequestration and depth of anaesthesia, are given as
follows.
Permeability coefficient
The permeability coefficient of propofol across the blood-
brain barrier is 0.51 l min-1 [8]. The permeability coeffi-
cient across the blood-CSF barrier is assumed to be 5000
times smaller than that across the blood-brain barrier
because of the smaller area of the blood-CSF barrier. The
permeability coefficients at other extracranial vascular
walls are deduced by assuming a vascular permeability
comparable to that of the blood-brain barrier. The refer-
ence permeability coefficient between the mass and blood
compartments is 30.58 l min-1 in the pulmonary segment,
0.14 l min-1 in the visceral segment, 0.53 l min-1 in the
muscular segment and 39.27 l min-1 in the residual seg-
ment.
The permeability is temperature-dependent and is given
by the Arrhenius equation:
where k0 (l min-1) is the reference propofol permeability at
steady-state temperature T0 (°C), E0 (kcal mol-1) is the
Arrhenius activation energy (7 kcal mol-1 in the cranial
segment and 5 kcal mol-1 in the other segments [10]), and
R is the universal gas constant (1.987 cal mol-1 K-1).
Total body clearance
Propofol is extensively metabolized and excreted in the
urine, mainly as inactive metabolites. Total body clear-
ance ranges from 23–50 ml kg-1  min-1  [12,15]. It is
assumed to be discharged from the visceral blood com-
partment.
Total body clearance is temperature-dependent as the
enzymes that metabolize propofol are temperature-sensi-
tive. The Van't Hoff equation is used to describe the tem-
perature dependence of propofol clearance:
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where e0 (ml kg-1 min-1) is the reference propofol clear-
ance at steady-state temperature T0 (°C), e0 = 23 ml kg-1
min-1, and Q10 is assumed to be 2 [10].
Tissue/water partition coefficient
The data on tissue/water partition coefficients of propofol
given by Weaver and colleagues [17] are used: 113.2 for
brain mass, 86.2 for visceral mass, 5.3 for pulmonary
mass, 51.6 for muscular mass and 35.0 for blood. The
CSF/water partition coefficient is assumed to be 1.0. The
residual-mass/water partition coefficient is 4700 because
of the high fat/water partition coefficient [9].
Pulmonary sequestration
Pulmonary sequestration, introduced by Levitt and Sch-
nider [9] in their PBPK model, is considered in this model.
The fraction of the dose sequestered by the lungs is 40%,
and the time constant of release of this sequestered propo-
fol into the pulmonary blood compartment is 80 min [9].
Anaesthesia depth
Clinically relevant blood concentrations of propofol
include 1–2 µg ml-1 for long-term sedation in the inten-
sive care unit, at least 2.5 µg ml-1 for satisfactory hypnosis,
and 3–11 µg ml-1 for maintenance of satisfactory anaes-
thesia [18]. The empirical anaesthesia of Roberts' step-
down infusion scheme for general anaesthesia in clinical
practice targets a blood concentration of 3 µg ml-1 [5].
These data are considered to be a quantitative scale for the
depth of propofol anaesthesia.
Model verification
As the thermoregulatory and hemodynamic parts of the
integrative model have been well validated previously
[10,11], only the pharmacokinetic part is verified here.
Various propofol infusion rates are assumed, and the sim-
ulation results for the transient behaviour of the model
are compared with published clinical data or theoretical
results.
Cerebrospinal fluid concentration
Engdahl and colleagues [14] measured the propofol con-
centration in the arterial blood and that in the CSF simul-
taneously in neurosurgical patients with respect to a step-
down propofol infusion. The anaesthesia was induced
with a bolus of propofol (2 mg kg-1) within 2 min and
maintained with a continuous infusion of propofol com-
mencing 5 min after the start of induction at an initial
infusion rate of 8 mg kg-1 h-1 for 15 min and then reduced
to 6 mg kg-1 h-1. A similar manner of propofol infusion is
assumed for the pharmacokinetic model. The propofol
concentration in the arterial blood and that in the CSF
were simulated. The results are shown in Fig. 2; the clini-
cal data of Engdahl and colleagues [14] are also shown for
comparison.
The simulated blood propofol concentrations at 2.5, 5, 15
and 30 min were 6.4, 2.1, 2.3 and 2.0 µg ml-1, respectively,
as shown in Fig. 2(a). The concentration of propofol in
the blood increased rapidly during induction. After the
bolus was administered, the concentration decreased rap-
idly. This is consistent with the pharmacokinetics of pro-
pofol; that is, its rapid clearance from the blood produces
the fast recovery characteristic of the drug. During anaes-
thesia maintenance, the concentration in the blood
increased progressively although it depended on the infu-
sion rate. This reflects the accumulation of propofol in the
blood. However, a plateau concentration was reached.
As shown in Fig. 2(b), the simulated CSF propofol con-
centrations increased during the 30-min simulation. The
concentration of propofol in the CSF increased more
slowly during induction than it did in the blood. The con-
centrations at 2.5, 5, 15 and 30 min were 9.1, 22.0, 41.1
and 41.6 ng ml-1, respectively. The concentration at 30
min was 2.1% of the blood concentration. These results
show that the CSF propofol concentration is positively
correlated with, and much lower than, the blood propofol
concentration.
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Response of (a) blood and (b) CSF propofol concentration to  short-term infusion Figure 2
Response of (a) blood and (b) CSF propofol concentration to 
short-term infusion. Results for pharmacokinetic part of inte-
grative model are compared with clinical data [14].
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All the simulation results agree well with the clinical data.
Engdahl and colleagues [14] reported that, for a similar
manner of propofol infusion in neurosurgical patients,
the blood propofol concentration increased rapidly dur-
ing induction and reached a plateau concentration (mean
2.24 µg ml-1) in about 5 min, which is comparable to our
simulation results. In their report, the CSF propofol con-
centration showed a slower increase during induction and
remained almost constant at 35.5 ng ml-1 15–30 min after
induction. It was estimated to be 50- to 100-fold lower
than that in blood.
Altogether, the blood and CSF propofol concentrations
predicted by the model are comparable to the clinical data
for short-term (30 min) infusion.
Arterial blood concentration
Levitt and Schnider [9] developed a PBPK model for pro-
pofol and verified it by comparing simulation results with
experimental data. The propofol infusion scheme used for
both the simulation and clinical experiment was the
application of an initial bolus (about 20 s) dose of 2 mg
kg-1 body weight followed 60 min later by a 60-min con-
stant infusion at 6 mg kg-1 h-1.
The same dosage was assumed for the pharmacokinetic
part of the integrative model, and the response of the
blood propofol concentration was simulated and com-
pared to the results with the established PBPK model.
It is observed in Fig. 3 that, in response to a bolus infu-
sion, the blood propofol concentration in the model
increased quickly during the injection phase (0–20 s) and
reached a peak value of 8.9 µg ml-1 at about 36 s. This is
consistent with the clinical observation that propofol
action is usually observed within 40 seconds [12]. In con-
trast, the propofol concentration in brain mass reached a
peak value of 8.6 µg ml-1 at about 4 min (data not shown).
After the bolus injection, the blood concentration
decreased to the eye-opening value (1 µg ml-1) at about 8
min and then to 0.15 µg ml-1 at 1 h. Altogether, this
impulse-like response of the blood propofol concentra-
tion in the integrative model agrees with the theoretical
results of the PBPK model.
As shown in Fig. 3, the blood propofol concentration
increased progressively during constant propofol infusion
for 1–2 h after induction and reached a peak value of
about 3.1 µg ml-1 at the end of infusion. It subsequently
decreased rapidly. The eye-opening blood concentration
(1 µg ml-1) was reached about 15 min after the end of
infusion. This time is close to that obtained with the PBPK
model and that for clinical observation (about 13 min for
normal patients) [9].
Altogether, the current model is comparable to the estab-
lished PBPK model in modelling short-term (0–1 h) and
long-term (10 h) propofol kinetics.
Application of model to propofol anaesthesia
Scheme for using propofol anaesthesia therapeutically
As shown in Fig. 4, our scheme for using propofol anaes-
thesia for hypothermic intracranial decompression con-
sists of four steps corresponding to a clinical scenario for
automatically regulating propofol administration and
therapeutic cooling to control elevated ICP. The proposed
scheme is simulated in the integrative model as follows.
(a) Hypothermic intracranial decompression
The elevated ICP is decreased by inducing therapeutic
cooling. It is simulated in the hemodynamic part of the
integrative model using a previously-developed propor-
tional-integral-derivative (PID) feedback temperature
controller [11].
(b) Brain temperature prediction
The brain temperature is reduced by the therapeutic cool-
ing in Step (a). The cooled brain temperature is predicted
using the thermoregulatory part of the integrative model.
(c) Concentration calculation
The minimum blood propofol concentration necessary
for inhibiting the thermoregulatory response is calculated
mathematically using the propofol-threshold mechanism of
(1). The thermoregulatory threshold determined by the
blood propofol concentration is assumed to be slightly
(0.01°C in this simulation) below the predicted cooled
brain temperature. A σ of 0.6°C (µg ml-1)-1 and a T0thres of
36.5°C are used in (1) since the blood propofol concen-
tration at which shivering is inhibited is slightly less than
that at which vasoconstriction is inhibited.
Response of blood propofol concentration to long-term infu- sion Figure 3
Response of blood propofol concentration to long-term infu-
sion. Results for pharmacokinetic part of integrative model 
are compared with those for PBPK model [9].
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(d) Propofol administration
The simulated rate of propofol administration is control-
led by a PID feedback propofol controller so as to realize
the minimum blood propofol concentration determined
in Step (c). The controller is designed on the basis of the
dynamic response of the propofol kinetics corresponding
to step-like propofol infusion.
Preliminary simulation
Prior to simulation of the novel propofol anaesthesia, the
integrative model was adjusted to represent a real patient
with intracranial hypertension. A PID feedback tempera-
ture controller and a PID feedback propofol controller
were defined on the basis of the dynamic responses of the
integrative model.
Model of intracranial hypertension
Various pathophysiological states of elevated ICP have
been simulated by adjusting the hemodynamic parame-
ters of the integrative model [10,11]. For example, the
absorption rate of CSF from the CSF compartment into
the venous compartment could be assumed to be 80% of
its normal value. This simulates the presence of a commu-
nicating hydrocephalus in clinical practice. Owing to this
adjustment, the ICP increased to about 24.5 mmHg [11].
The manipulated model of intracranial hypertension is
considered to be the patient in this theoretical discussion.
Therapeutic cooling is used to decrease the elevated ICP of
the model to 15 mmHg, and propofol anaesthesia for the
intracranial decompression is simulated in the proposed
and empirical schemes.
Illustration of proposed scheme for using propofol anaesthesia for hypothermic intracranial decompression: (a) hypothermic  intracranial decompression, (b) brain temperature prediction, (c) concentration calculation, (d) propofol administration Figure 4
Illustration of proposed scheme for using propofol anaesthesia for hypothermic intracranial decompression: (a) hypothermic 
intracranial decompression, (b) brain temperature prediction, (c) concentration calculation, (d) propofol administration. The 
propofol-threshold mechanism is a linear relationship between blood propofol concentration and thermoregulatory threshold.
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PID temperature controller
The transient behaviour of the ICP in intracranial hyper-
tension during brain hypothermia treatment was simu-
lated by reducing the cooling temperature from 30 to
29.5°C and then to 29°C [11]. The systemic relationship
between the elevated ICP and the cooling temperature is
approximated by a linear transfer function:
where Ghypot denotes the transfer function from the cooling
temperature to ICP, s denotes the Laplace operator, khypot is
the static gain (9.9 mmHg°C-1), and τ hypot1 and τ hypot2 are
time constants (19.2 and 0.3 h, respectively).
The PID feedback temperature controller is positioned as
shown in Fig. 5.
where Tcooling (°C) denotes the therapeutic cooling temper-
ature, T0cooling is its normal value (30°C), eicp (mmHg) is
the controlled error of ICP (eicp(t) =   - Pcsf(t), where
 is the reference ICP and   = 15 mmHg), and KP,
KI, and KD are PID feedback control coefficients.
where λ hypot is an adjustable parameter used to improve
the feedback control. In this simulation, λ hypot = 3.5 h.
PID propofol controller
The position of the PID feedback propofol controller used
to realize the minimum blood propofol concentration is
shown in Fig. 4. The PID feedback propofol controller is
achieved by simulating the blood propofol concentration
response to a constant propofol infusion rate of 1 mg kg-1
h-1  using the pharmacokinetic part of the integrative
model. With the help of the System Identification Tool-
box of Matlab (version 7.0.4), we use the following trans-
fer function to approximate the dynamic response of
blood propofol concentration to propofol infusion:
where Gpropl denotes the transfer function from the propo-
fol infusion rate to the blood propofol concentration,
kpropl is the static gain (0.56 µg ml-1 (mg kg-1 h-1)-1), and τ
propl1 and  τ  propl2 are time constants (1.74 and 0.12 h,
respectively).
The static gain, kpropl, of the transfer function Gpropl(s)
implies that continuous infusion of propofol at 5–6 mg
kg-1 h-1 will result in a blood concentration of about 3 µg
ml-1. This is consistent with the clinical observation that a
blood concentration of 3 µg ml-1 is achieved by tuning the
infusion rate to around 6 mg kg-1 h-1 in the empirical Rob-
erts' anaesthesia scheme [5]. Therefore, the estimated
transfer function, Gpropl(s), is considered a reasonable
approximation of the propofol kinetics.
On the basis of Gpropl(s), we developed a PID feedback
controller to tune the propofol infusion rate to achieve the
target blood propofol concentration.
where Ipropl (mg kg-1 h-1) is the propofol infusion rate, econcn
(µg ml-1) is the controlled error of the blood propofol
concentration (econcn(t) =   - Cartery(t) , where 
is the target blood propofol concentration, which is calcu-
lated from the propofol-threshold mechanism represented by
(1)), and λ propl = 3.0 min.
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Actual simulation
The proposed scheme for administering propofol anaes-
thesia for hypothermic intracranial decompression was
simulated using the integrative model. For comparison,
the empirical scheme of Roberts' step-down propofol
infusion, that is, 1 mg kg-1 (0–2 min), 10 mg kg-1 h-1 (2–
10 min), 8 mg kg-1 h-1 (10–20 min) and 6 mg kg-1 h-1 (20
min to end of simulation) were also simulated.
Results
As shown in Fig. 6(a), the elevated ICP (24.5 mmHg) was
reduced to below 20 mmHg about 2.5 h after inducing the
therapeutic cooling and reached the reference ICP (15
mmHg) at about 8 h. The maximum speed of decrease
was 2.55 mmHg h-1 at about 2 h. No overshoot of the con-
trolled ICP was observed. These quantitative characteris-
tics depend on the therapeutic cooling temperature
determined by the PID feedback temperature controller.
The cooling temperature, which is also shown in Fig. 6(a),
was ~25°C at 0.25 h and then increased as the ICP
decreased. The highest cooling temperature was ~29°C at
about 7 h. The simulated cooling temperature never
exceeded the reference value (30°C). This ambient cool-
ing reduced the brain temperature. The static gain of the
reduced brain temperature with reference to the cooling
temperature was ~2°C°C-1, as their values at the end of
simulation were 28.9 and 34.7°C, respectively. A cooled
brain temperature of 34–35°C corresponds to mild hypo-
thermia, which causes fewer complications than moderate
hypothermia (32–33°C) [4]. These results demonstrate
that dynamic regulation of the cooling temperature for
intracranial decompression is clinically practicable.
The controlled propofol concentrations in the blood and
brain mass are shown in Fig. 6(b). During most of the
simulated period, the proposed anaesthesia scheme
induced propofol concentrations of 3–3.5 µg ml-1  in
blood and 10–12 µg ml-1 in brain mass. In contrast, the
empirical scheme resulted in propofol concentrations of
3.5–4 µg ml-1 in blood and 12–14 µg ml-1 in brain mass.
Therefore, the empirical scheme induces deeper anaesthe-
sia than the proposed scheme. The finding that empirical
anaesthesia induces a blood concentration of 3.5–4 µg ml-
1 is consistent with clinical observations [5].
As shown in Fig. 6(b), the propofol concentrations in the
blood and brain mass were higher over the period 3.7–7.7
h with the proposed scheme than with the empirical
scheme. As the controlled brain temperature was much
lower during this period, this observation is reasonable.
Clinically, a blood propofol concentration of more than
2.5 µg ml-1 is necessary for satisfactory hypnosis and 3–11
µg ml-1 is needed to maintain satisfactory anaesthesia.
Therefore, the anaesthesia induced with the proposed
scheme, as well as with the empirical scheme, is consid-
ered satisfactory.
As shown in Fig. 6(c), the simulated propofol administra-
tion varied dynamically in accordance with the cooling
temperature. During the first hour, no propofol was nec-
essary although the cooling temperature was somewhat
low. This is consistent with the observation that the brain
temperature is still higher than the thermoregulatory
thresholds during this initial period. In contrast, the infu-
sion rate was high in the first half hour with the empirical
scheme.
The total dosage with the proposed scheme was more
than 18% less than with the empirical scheme (total dos-
age of 146.7 mg kg-1 with the empirical scheme and 119.8
mg kg-1 with the proposed one). As pointed out by McK-
eage and Perry [12], a higher than necessary dosage leads
to a higher blood propofol concentration, which may
result in a longer recovery time. Therefore, the propofol
administration represented by the PID feedback propofol
controller is more appropriate for clinical application
than the empirical step-down infusion scheme.
The propofol concentrations in the blood and brain mass
were higher when the empirical scheme was used with
therapeutic cooling than without cooling (data not
shown). The temperature threshold with the empirical
anaesthesia scheme, as determined in accordance with the
propofol-threshold mechanism of (1), is shown in Fig. 6(a).
It indicates that additional propofol should have been
titrated during the 3.7–7.7 h period with the empirical
scheme because the cooled brain temperature was below
the threshold. Therefore, the total dosage with the empir-
ical scheme would be even larger than with the proposed
scheme.
Given the controlled propofol concentration in the blood
and brain mass, the lesser depth of anaesthesia and the
lower amount of the total dosage, we conclude that the
proposed propofol infusion scheme is more appropriate
than the empirical scheme.
Discussion
Brain hypothermia treatment is used for brain-injured
patients to protect the brain against secondary neuronal
death [4]. It has been shown to reduce elevated ICP effec-
tively in the intensive care unit [2,3]. The major mecha-
nism of intracranial decompression is related to the
reduction of cerebral metabolism by therapeutic hypo-
thermia [10,11]. Together with simultaneous manage-
ment of brain temperature and ICP, adequate anaesthesia
is an important component of intensive care. Propofol is
widely used in clinical practice, partly because it greatly
facilitates management of cardiopulmonary function [4]Theoretical Biology and Medical Modelling 2007, 4:46 http://www.tbiomed.com/content/4/1/46
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Simultaneous management of intracranial pressure, temperature and anaesthesia: (a) intracranial pressure, brain temperature  and cooling temperature, (b) propofol concentration response in blood and brain mass, (c) propofol infusion rate Figure 6
Simultaneous management of intracranial pressure, temperature and anaesthesia: (a) intracranial pressure, brain temperature 
and cooling temperature, (b) propofol concentration response in blood and brain mass, (c) propofol infusion rate.
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and partly because it results in a shorter, more predictable
emergence time than other sedatives [12]. However, the
primary effects of propofol anaesthesia are seldom esti-
mated when it is used for brain hypothermia treatment. In
particular, little information is available in the literature
on the use of propofol anaesthesia for hypothermic
intracranial decompression.
Although two physiologically-based pharmacokinetic
(PBPK) models for propofol have recently been devel-
oped [8,9], the effects of hypothermia on propofol kinet-
ics have not been considered in the literature. In contrast,
we previously developed an integrative model consisting
of the thermoregulatory, the hemodynamic and the phar-
macokinetic subsystems of a patient under brain hypo-
thermia treatment [10,11]. The interactions among these
subsystems are considered via the circulating blood and
the temperature-dependence mechanism of various phys-
iological functions such as the metabolism, vascular per-
meability and drug clearance [11]. By changing its
pharmacokinetic part to describe propofol kinetics, we
can use this integrative model to simulate the effects of
propofol anaesthesia during hypothermia.
The current model is comparable to the PBPK model
developed by Levitt and Schnider [9] in modelling short-
term (0–1 h) and long-term (10 h) propofol kinetics.
However, it is better than the established PBPK model in
describing interactions with other physiological func-
tions, such as the thermoregulatory subsystem and the
ICP-centered hemodynamics. Furthermore, the pharma-
cokinetic part of the integrative model describes the tissue
and its capillary blood in two adjacent compartments, so
it better describes capillary permeability and better repre-
sents flow-limited propofol pharmacokinetics.
Compared with the previously-developed integrative
model, the present model acquires its originality particu-
larly by introducing the propofol-threshold mechanism,
which is a pre-established relationship between the blood
propofol concentration and the thermoregulatory thresh-
old. Owing to this mechanism, the thermoregulatory sub-
system is pharmacodynamically related to the propofol
kinetics. That is, a reference blood propofol concentration
can be determined to maintain the propofol-determined
thermoregulatory threshold below the actual cooled brain
temperature.
Using the integrative model and the propofol-threshold
mechanism, we developed a propofol anaesthesia scheme
for hypothermic intracranial decompression. This uses
two feedback controllers: a PID feedback temperature
controller for tuning the therapeutic cooling and a PID
feedback propofol controller for tuning the propofol infu-
sion rate.
As shown by the simulation results, both therapeutic cool-
ing to reduce the elevated ICP and propofol anaesthesia to
inhibit the thermoregulatory responses were achieved
with the integrative model and the proposed anaesthesia
scheme. This proposed scheme is a closed-loop system
that facilitates decision-making about propofol adminis-
tration so as to induce cooling and to reach and maintain
a preset target ICP automatically.
As it is still in an initial development stage, the present
model depends on some simplification. Therefore, it has
some limitations. First, propofol anaesthesia may reduce
cerebral metabolism, elevated ICP, cerebral blood flow
and cardiac output. However, the pharmacodynamic
effects of propofol are ignored. Second, the model
depends on several assumptions, including constant vas-
cular resistance, hepatic blood flow, protein and colloid
osmotic pressure in the blood, and pulmonary sequestra-
tion. Third, the parameters may have a highly dynamic
course and differ significantly in importance from one
patient to another. Such inter-patient variability is not
considered in the present model. By incorporating these
physiological mechanisms, we should be able to improve
the prediction performance of the model.
Despite these model limitations, our theoretical analysis
based on the integrative model has provided useful
insights into the simultaneous management of various
physiological functions as well as into the automation of
medical treatment using closed-loop control techniques.
The current theoretical discussion should help improve
understanding of the clinical use of propofol anaesthesia
for hypothermic intracranial decompression. Given the
insights provided by the simulation results, an in situ
study of the proposed anaesthesia scheme should be fruit-
ful.
Conclusion
We have used a previously-developed integrative model of
the thermoregulatory, hemodynamic and pharmacoki-
netic subsystems to simulate the use of propofol anaesthe-
sia for hypothermic intracranial decompression. A
pharmacodynamic relationship between the blood pro-
pofol concentration and the thermoregulatory threshold
was introduced to combine the thermoregulation subsys-
tem with the propofol kinetics. A novel scheme for
administering propofol anaesthesia was proposed and
simulated using the integrative model. Theoretical results
suggest that the proposed anaesthesia scheme is more
appropriate than the empirical one.
Appendix
Propofol kinetics is described mathematically on the basis
of the mass conservation law. As an example, consider
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where   and   denote the distributed volume and
propofol concentration in compartment Y of segment X,
kBCB and kBBB are the permeability coefficient at the blood-
CSF barrier and blood-brain barrier, respectively, kbrain is
the permeability coefficient between the brain mass and
CSF,   represents the blood flow from the arterial
compartment into the cranial blood compartment, 
represents the blood flow from the cranial blood compart-
ment into the venous compartment, λ csf, λ blood and λ brain
are the CSF/water, blood/water and brain/water partition
coefficients of propofol, respectively.
Thirteen differential equations of propofol concentrations
are available for describing the pharmacokinetics of pro-
pofol.
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